TCGA-AC-A62Y-01A-11R-A29R-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 18
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.490
- INTERFERON_ALPHA_RESPONSE+0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.360
- INFLAMMATORY_RESPONSE+0.340
- INTERFERON_GAMMA_RESPONSE+0.340
- PANCREAS_BETA_CELLS+0.330
- APOPTOSIS+0.310
- COMPLEMENT+0.310
- KRAS_SIGNALING_UP+0.300
- FATTY_ACID_METABOLISM+0.290
Top 10 suppressed
- MITOTIC_SPINDLE-0.460
- MYC_TARGETS_V2-0.460
- G2M_CHECKPOINT-0.410
- WNT_BETA_CATENIN_SIGNALING-0.380
- E2F_TARGETS-0.340
- MYC_TARGETS_V1-0.330
- UNFOLDED_PROTEIN_RESPONSE-0.320
- APICAL_JUNCTION-0.280
- HEDGEHOG_SIGNALING-0.250
- PI3K_AKT_MTOR_SIGNALING-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-67-3773-01A-01R-0946-07 | — | cohortA1 | 0.871 |
| 2 | TCGA-97-8177-01A-11R-2287-07 | — | cohortA1 | 0.850 |
| 3 | SRR6013535 | — | cohortMD2 | 0.842 |
| 4 | SJEPD013_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.841 |
| 5 | MDT-AP-0499 | Med | Medulloblastoma | 0.832 |
| 6 | TCGA-67-3772-01A-01R-0946-07 | — | cohortA1 | 0.828 |
| 7 | SRR8518286 | — | F | 0.827 |
| 8 | da7cbc0a-95dc-4303-a5dd-75857c066f3b | — | — | 0.826 |
| 9 | SRR1079591 | GTEX | — | 0.822 |
| 10 | AUR-AFUL-TTP1-A-1-1-R-A743-41 | — | C | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.490 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.360 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| UV_RESPONSE_UP | 0.260 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |